Pages that link to "Q34204047"
Jump to navigation
Jump to search
The following pages link to Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. (Q34204047):
Displaying 38 items.
- Immune correlates of vaccine protection against HIV-1 acquisition (Q26778573) (← links)
- A global approach to HIV-1 vaccine development (Q27024614) (← links)
- Human Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic Structure (Q27676155) (← links)
- Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals (Q27677941) (← links)
- The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel (Q30152923) (← links)
- An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates. (Q30375785) (← links)
- Controlling the HIV/AIDS epidemic: current status and global challenges (Q30420558) (← links)
- Superinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus (Q34312037) (← links)
- Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response. (Q34540352) (← links)
- Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits. (Q34863513) (← links)
- Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C. (Q35061529) (← links)
- Computational prediction of neutralization epitopes targeted by human anti-V3 HIV monoclonal antibodies (Q35108505) (← links)
- Cholera toxin B: one subunit with many pharmaceutical applications (Q35232735) (← links)
- A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site (Q35706462) (← links)
- A critical question for HIV vaccine development: which antibodies to induce? (Q35783015) (← links)
- Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially (Q36249053) (← links)
- Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors (Q36384117) (← links)
- Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design (Q36447540) (← links)
- Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides. (Q36920319) (← links)
- Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals (Q37130745) (← links)
- Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines. (Q37419234) (← links)
- Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits (Q37448281) (← links)
- Improvement of antibody responses by HIV envelope DNA and protein co-immunization. (Q37588371) (← links)
- Prospects for an HIV vaccine: leading B cells down the right path (Q37964482) (← links)
- Neutralizing antibodies and control of HIV: moves and countermoves. (Q37971867) (← links)
- Basic research in HIV vaccinology is hampered by reductionist thinking (Q38025633) (← links)
- Broadly neutralizing antibodies against HIV-1: templates for a vaccine (Q38065391) (← links)
- Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies (Q38220506) (← links)
- Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens (Q38581943) (← links)
- Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains (Q41610618) (← links)
- Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes. (Q42204816) (← links)
- Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials. (Q47555452) (← links)
- Neutralization tiers of HIV-1. (Q47562235) (← links)
- Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. (Q53693698) (← links)
- Oligomannose Glycopeptide Conjugates Elicit Antibodies Targeting the Glycan Core Rather than Its Extremities (Q63362961) (← links)
- Immune Correlates of Disease Progression in Linked HIV-1 Infection (Q64269048) (← links)
- Unbiased Identification of Immunogenic Staphylococcus aureus Leukotoxin B-Cell Epitopes (Q89516785) (← links)
- Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates (Q92803580) (← links)